Newscast – Page 181 – media

Tumor-targeting MRI contrast developed, based on human protein

A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including early stage tumor detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.
- Source: drugdu
- 454
- July 7, 2017
breast cancer Clinical New Approvals tumor
Trillion in search of new partners

Trillium Therapeutics is seeking new partners as it looks over its pipeline with an eye to the future.
- Source: fiercebiotech
- 842
- July 5, 2017
EMA EU Market Views
MPs keen for close collaboration with EMA post Brexit

British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.
- Source: pharmatimes
- 938
- July 4, 2017
Company Insight EMA EU
Novartis bags first-line approval for Zykadia

The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
- Source: pharmatimes
- 519
- June 30, 2017
cancer Company Insight New Approvals NSCLC Zykadia
Beta blockers may protect against heart failure

In a study conducted at York University, scientists came to the astonishing conclusion that beta blockers could protect against heart failure. This was one of the latest discoveries in a field with endless treatments managing symptoms though previously damage sustained to the heart can’t be revered.
- Source: Ddu
- 458
- June 30, 2017
beta blocker heart mortality New Approvals
FDA approval granted to Emmaus for sickle cell therapy

Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
- Source: Ddu
- 528
- June 29, 2017
Endari FDA formulation New Approvals
LifeArc teams up with UK defence lab and Canada’s CDRD

LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
- Source: pharmatimes
- 615
- June 29, 2017
antibacterial LifeArc Market Views Researches
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: Pharmtimes
- 872
- June 28, 2017
Clinical Trials EU mepolizumab
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: pharmatimes
- 853
- June 28, 2017
asthma Company Insight EU surgery
EU regulators reviewing Shire’s bleeding disorder drug

European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
- Source: pharmatimes
- 631
- June 26, 2017
EU FDA genetic therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.